• 2'3'-cGAMP (Sodium Salt): High-Affinity STING Pathway Activa

  2026-07-21

  2'3'-cGAMP (sodium salt) is a potent, endogenous STING agonist with nanomolar affinity, enabling precise dissection of innate immune signaling. Its high aqueous solubility and stability make it a gold-standard reagent for mechanistic and translational research into cGAS-STING pathway activation, immunotherapy, and interferon induction.

• Cerulenin’s Targeted Inhibition of Leucomycin Biosynthesis i

  2026-07-21

  This study demonstrates that cerulenin, a fatty acid synthesis inhibitor, specifically impedes the biosynthesis of leucomycin, a 16-membered macrolide antibiotic, in Streptomyces kitasatoensis. The research elucidates the polyketide pathway origins of macrolide antibiotics and provides mechanistic clarity on how lipid synthesis inhibitors can modulate secondary metabolite production, with implications for both antibacterial drug resistance research and the design of macrolide analogs.

• Microbiota and Metabolome Shifts in E. tenella-Infected Chic

  2026-07-20

  This study profiles the effects of ethanamizuril, sulfachlorpyridazine, and their combination on the cecal microbiota and metabolome in chickens challenged with Eimeria tenella. Using microbial and metabolomic analyses, the research highlights drug-induced shifts in gut ecology and metabolic function, providing new insight into monitoring anticoccidial efficacy.

• BX795: Precision PDK1 Inhibition for Advanced In Vitro Cance

  2026-07-20

  Explore BX795, a potent PDK1 inhibitor, and its unique impact on in vitro cancer assay design and interpretation. This article reveals how BX795 empowers researchers to more precisely dissect proliferative and cytotoxic responses, integrating recent methodological innovations for rigorous drug evaluation.

• Aprotinin (BPTI): Applied Protocols and Troubleshooting in F

  2026-07-19

  Aprotinin (Bovine Pancreatic Trypsin Inhibitor, BPTI) stands out for its precise, reversible inhibition of serine proteases, empowering researchers to fine-tune workflows in cardiovascular surgery models, inflammation assays, and red blood cell studies. This guide bridges rigorous membrane biophysics with translational blood management, offering actionable parameters and expert troubleshooting for maximum experimental fidelity.

• Applied Firefly Luciferase mRNA: 5-moUTP for Robust Assays

  2026-07-18

  EZ Cap™ Firefly Luciferase mRNA (5-moUTP) from APExBIO sets a new benchmark in bioluminescent reporter assays by enabling immune-silenced, high-yield gene expression in mammalian systems. Its advanced cap structure and 5-moU modifications translate to superior mRNA stability, making it ideal for sensitive translation efficiency studies, cell viability assessments, and in vivo imaging.

• Gepotidacin (GSK2140944): Redefining Antibacterial Mechanism

  2026-07-17

  Explore how Gepotidacin (GSK2140944) offers a paradigm shift in antibacterial research by targeting bacterial DNA replication with unmatched selectivity. This article uniquely examines assay design, mechanistic depth, and practical advances beyond current protocols in antibiotic resistance research.

• Mc-Val-Cit-PABC-PNP: Technical Use in ADC Peptide Linker Wor

  2026-07-17

  Mc-Val-Cit-PABC-PNP addresses the need for a cathepsin B-cleavable ADC peptide linker in research workflows requiring targeted lysosomal payload release. It is optimized for organic solvent-based antibody-drug conjugate synthesis but is not suitable for aqueous, diagnostic, or clinical applications.

• ECL Chemiluminescent Substrate Detection Kit: Ultra-Sensitiv

  2026-07-16

  The ECL Chemiluminescent Substrate Detection Kit (Hypersensitive) empowers researchers to detect low-abundance proteins with picogram sensitivity and extended signal duration, transforming Western blot workflows. With robust HRP chemiluminescence and minimal background, this APExBIO kit streamlines protein detection on nitrocellulose and PVDF membranes while reducing reagent costs.

• Methicillin Sodium Salt: Mechanistic Precision and Assay Des

  2026-07-16

  Explore the scientific foundation and advanced laboratory applications of Methicillin sodium salt, a pivotal bacterial cell wall synthesis inhibitor. This in-depth analysis reveals how nuanced understanding of mechanism and resistance informs next-generation assay design and research rigor.

• Spleen-Targeted Neoantigen mRNA Vaccine Drives TLS in HCC

  2026-07-15

  Lin et al. report a spleen-targeted neoantigen mRNA vaccine (STNvac) that induces robust ISG15+ CD8+ T cell responses and promotes tertiary lymphoid structure (TLS) formation in hepatocellular carcinoma (HCC). Their findings elucidate a mechanistic link between spleen delivery, immune cell activation, and potent antitumor immunity, providing a foundation for next-generation mRNA vaccine strategies against solid tumors.

• Screening FDA-Approved Drugs Reveals Lopinavir as a MERS-CoV

  2026-07-15

  This study identifies Lopinavir (ABT-378) among four FDA-approved compounds that inhibit Middle East respiratory syndrome coronavirus (MERS-CoV) replication in vitro. The findings highlight the potential of repurposing known HIV protease inhibitors for emerging coronavirus research and inform future antiviral therapy development.

• Fast-Onset Antidepressants: Esflurbiprofen Disrupts SERT-nNO

  2026-07-14

  The referenced study identifies esflurbiprofen as a fast-acting antidepressant, mechanistically distinct from SSRIs, by targeting the SERT-nNOS interaction in the dorsal raphe nucleus. This work introduces a novel drug screening approach and highlights a promising direction for rapid-onset depression therapies.

• AAL-993: Advancing Tumor Angiogenesis Research with Selectiv

  2026-07-14

  Explore how AAL-993, a potent VEGF receptor inhibitor, enables advanced anti-angiogenic and tumor angiogenesis research. This article offers a deep scientific analysis, revealing how AAL-993's selectivity and mechanistic precision open new directions beyond current literature.

• Gepotidacin (GSK2140944): Protocols for Antibiotic Resistanc

  2026-07-13

  Gepotidacin's unique inhibition of bacterial DNA gyrase and topoisomerase IV empowers advanced workflows targeting multidrug-resistant pathogens. This article delivers actionable experimental protocols, troubleshooting strategies, and a translational bridge to clinical findings, making it indispensable for antibacterial research and antibiotic resistance studies.

442 records 10/30 page Previous Next First page 上5页 678910 下5页 Last page